neurogenesis

A former Microsoft executive is planning to create a marijuana enterprise that he hopes will dominate the legal cannabis industry during the “dot bong era” much like Starbucks dominates the coffee industry.

As more states make recreational marijuana legal, researchers fret about short- and long-term health effects

Several decades ago, a number of clinics used LSD to treat alcoholism with some success. But until now, no research has pulled together the results of these trials to document exactly how effective LSD was. Now a new meta-analysis of randomized controlled trials of the drug provides evidence for a clear and consistent beneficial effect of LSD for treating alcohol dependency.

PubMed comprises more than 22 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.

Founded in 1986, the Multidisciplinary Association for Psychedelic Studies (MAPS) is a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.MAPS furthers its mission by: Developing psychedelics and marijuana into prescription medicines; Training therapists and working to establish a network of treatment centers; Supporting scientific research into spirituality, creativity, and neuroscience; and educating the public honestly about the risks and benefits of psychedelics and marijuana.

For decades, the U.S. government banned medical studies of the effects of LSD. But for one longtime, elite researcher, the promise of mind-blowing revelations was just too tempting.

The issue of use patents for MDMA is very timely now that human studies can begin. MAPS has opened a Drug Master File for MDMA at the FDA and is preparing to sponsor FDA-approved MDMA research. If the research goes extraordinarily well, MAPS may one day have the opportunity and responsibility to manufacture and market MDMA to appropriately trained and licensed physicians. It could be a major setback if MAPS funded MDMA research and secured approval for its medical use only to have someone else control it through an inexpensively obtained use patent.

Fifty years after Tom Wolfe documented that epic LSD trip on a bus called “Further,” a new breed of scientists is attempting once again to put Schedule I drugs into words (peer-reviewed ones, thankfully). The rigorous and careful exploration of these substances points to four key benefits.

Meet the Scarsdale version of

A visual guide to the substances of The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds, by Alexander T. Shulgin, Tania Manning and Paul F. Daley., and related phenethylamines.

And how it became a psychedelic icon.